Oct 25, 2018
  1. Psoriasis a common, non-contagious, autoimmune disease affects about one adult in 50 worldwide1
  2. Many people suffer needlessly from psoriasis due to incorrect or delayed diagnosis, inadequate treatment options, insufficient access to care, and social stigmatization
  3. Novartis launched “Skin to Live In”, a Middle East regional integrated campaign launches specifically in United Arab Emirates last year to inspire hope and drive action. The campaign is expected to be launched soon in Egypt.

Cairo - October 25, 2018 – During the Sharm Derma Congress taking place in Cairo, October 24th – 27th, coinciding with World Psoriasis Day, Novartis Pharma S.A.E (Novartis Egypt) - in collaboration with the Egyptian Psoriasis Patient Society (under establishment) shed light on one of the world’s most prevalent autoimmune skin disorders, to help improve patients’ lives by promoting better understanding of the illness among the general public and healthcare professionals.

Prof. Assem Farag, President of the Sharm Derma Congress said, “This edition of the Sharm Derma Conference marks the beginning of many initiatives we have underway to raise awareness of psoriasis and take steps towards advancing patient care on many fronts. Despite its prevalence, psoriasis is one of the most misunderstood autoimmune skin disorders. Many people living with psoriasis experience anxiety, embarrassment and depression, they also face discrimination because others fear the condition is contagious. Our goal is to change that.”

“Psoriasis is a common, non-contagious, autoimmune skin disorder that affects almost 125 million people worldwide – about one adult in 501,” said Prof. Mahira El Sayed, former head of Ain Shams University Dermatology and Venereology Department, and Head of Egyptian Psoriasis Patient Society (under establishment) “It is not simply a cosmetic problem, but a persistent, chronic condition caused by skin cells multiplying up to 10 times faster than normal with the intense volume of red, scaly patches leading to pain, discomfort and even psychological problems.1

Psoriasis symptoms vary from person to person. Depending on type, areas of psoriasis can be as small as a few flakes on the scalp or elbow, or cover the majority of the body. The most common symptoms of plaque psoriasis are red, raised, inflamed patches of skin; whitish-silver scales or plaques on the red patches; dry skin that may crack and bleed; and soreness around patches, to name a few3. Risk factors include family history, viral and bacterial infections, stress and obesity. Physical and environmental triggers including cold temperatures, too much alcohol, smoking and having another autoimmune disorder can all contribute to developing psoriasis or increasing its severity.3,10,11

Prof. Magdy Ragab, Professor of Dermatology and Venereology, Alexandria University, spoke of the diagnosis and treatment of psoriasis, “For many patients, the road to diagnosis is long and arduous, and involves trying various therapies to manage their symptoms. The World Health Assembly highlighted that many people suffer needlessly from psoriasis due to incorrect or delayed diagnosis, inadequate treatment options, insufficient access to care, and because of social stigmatization.”

He also spoke of treatment goals saying, “Clear skin is the aim of psoriasis treatment, and a Psoriasis Area and Severity Index (PASI) 75, 90 or 100 response is considered an important measure of treatment success. Treatment options include topical creams, oral pills, phototherapy and biologics - the most recent and effective form of therapy.4-6

A Psoriasis Patient shared first-hand experience about living with and overcoming psoriasis, “Psoriasis was a tremendous burden to live with, one that I have fought for many years, and still fight. With my family’s great support, I was able to overcome so many challenges. By finding the right dermatologist and right treatment, I am now finally able to control my psoriasis instead of having it control my life,” he said.

Prof. Mahira addressed the need to raise awareness saying, “Healthcare providers need more psoriasis education and training, particularly within primary care settings through a network of specialists, including dermatologists, rheumatologists and psychologists. Patients and families should foster the development of organizations that can provide education, counseling and care programs for people with psoriasis.”

Dr. Assem Farag shared Novartis’s “Skin to Live” Middle East regional campaign launched specifically in the UAE in 2017, saying, “Novartis has been at the forefront of raising awareness about critical disease areas, including psoriasis, with the launch of an integrated campaign designed to inspire hope and drive action for patients to break free from the challenges of living with psoriasis. This is a groundbreaking regional patient activation endeavor seeking to empower all those affected by psoriasis, and encourage them to take proactive steps to overcome its challenges. This campaign is expected is be launched soon in Egypt.”

# # #

About Novartis

Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach nearly 1 billion people globally and we are finding innovative ways to expand access to our latest treatments. About 125 000 people of more than 140 nationalities work at Novartis around the world. Find out more at https://www.novartis.com/.

Novartis Egypt Media Relations

E-mail: [email protected]

Reem El Adl
Head of Corporate Communications and Patient Advocacy
[email protected]

Shahista Hussien
Corporate Communications Manager
[email protected]

للنسخة العريية الرجاء الضغط هنا

اقرأ أكثر(PDF 0.2,MB)


  1. who.int/gho/countries/egy.pdf?ua=1 last accessed July 2017
  2. http://www.egyptindependent.com/egyptians-are-fattest-africans-says-who/ last accessed July 2017
  3. Modified from Gottlieb A, et al. Am J Med 2009;122:1150; Kurd SK, et al. Arch Dermatol 2010;146:891;
    Cohen A, et al. JEADV 2009;23:561 .psoriaticarthritisinfo.ca/symptoms-of-psa/ last accessed March 2018
  4. skintolivein.com
  5. Hartshorne Clin Exp Derm 2003
  6. Shelleh et al SMJ 2004, Alakloby et al SMJ 2005
  7. Revicki DA et al. Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasis. Dermatology. 2008;216:260-270.
  8. https://www.webmd.com/skin-problems-and-treatments/psoriasis/news/200712... last accessed March 2018.
  9. WHO report – 2017 www.who.int/iris/handle/10665/204417 last accessed March 2017 - Mrowietz et al 2014
  10. https://www.healthline.com/health/psoriasis#symptoms-of-psoriasis
  11. https://www.mayoclinic.org/diseases-conditions/psoriasis/symptoms-causes...


This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “expect,” “anticipate,” “look forward,” “believe,” “committed,” “investigational,” “pipeline,” “launch,” or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political and economic conditions; safety, quality or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.